Xitoyda farmatsevtika sanoati - Pharmaceutical industry in China - Wikipedia

Ushbu maqola bo'lishi kerak yangilangan. Iltimos, ushbu maqolani so'nggi voqealarni yoki yangi mavjud ma'lumotlarni aks ettirish uchun yangilang. (2016 yil noyabr)

Farmatsevtika sanoati sanoatning etakchi tarmoqlaridan biridir Xitoy Xalq Respublikasi sintetik kimyoviy moddalar va giyohvand moddalarni, tayyorlangan xitoy dori-darmonlarini, tibbiy buyumlarni, apparatlar va asboblarni, gigiena materiallarini, qadoqlash materiallarini va farmatsevtika mashinalari.

Dunyo aholisining 20 foizi Xitoyga to'g'ri keladi, ammo butun dunyo aholisining atigi 1,5 foizi dori bozor. Xitoy sog'liqni saqlash sharoitlarini o'zgartirish asosiyni kengaytirish uchun mo'ljallangan tibbiy sug'urta aholining katta qismini qamrab oladi va jismoniy shaxslarga mahsulot va xizmatlardan keng foydalanish imkoniyatini beradi. O'zgarishlar davridan keyin farmatsevtika sanoatining kengayishi davom etishi kutilmoqda.^[1]

2007 yilga kelib, Xitoyda 3000 dan 6000 gacha mahalliy farmatsevtika ishlab chiqaruvchilari va 14000 ga yaqin mahalliy farmatsevtika distribyutorlari mavjud. Bozorda tez-tez keltirilgan salbiy omillarga himoya etishmasligi kiradi intellektual mulk huquqlari, giyohvand moddalarni tasdiqlash protseduralarining ko'rinmasligi, samarali davlat nazoratining etishmasligi, giyohvand moddalarni tadqiq qilish uchun korporativ yordamning pastligi va davolash mahalliy va xorijiy firmalarga berilgan Xitoyda.^[2] Shunga qaramay, Xitoy 2011 yilga kelib dunyodagi uchinchi yirik farmatsevtika bozoriga aylanishi kutilmoqda.^[3]

Shanxay giyohvand moddalarni o'rganish bo'yicha eng muhim global markazlardan biriga aylanishi bilan izlanishlar va rivojlanishlar ko'paymoqda. Eng muhimi, Novartis da yirik tadqiqot va rivojlantirish bazasini tashkil etishi kutilmoqda Shanxay bu uning giyohvandlik rivojlanishining ustuni bo'ladi.^[4]

Business China ma'lumotlariga ko'ra, Xitoyning minglab mahalliy kompaniyalari bozorning 70 foizini, eng yaxshi 10 ta kompaniyaning 20 foizini tashkil qiladi. Aksincha, aksariyat rivojlangan mamlakatlarning eng yaxshi 10 kompaniyasi bozorning yarmiga yaqinini nazorat qiladi. 2004 yil 30 iyundan boshlab Davlat oziq-ovqat va farmatsevtika idorasi (SFDA) yangi GMP standartlariga javob bermaydigan ishlab chiqaruvchilarni yopmoqda. Chet ellik o'yinchilar hisob-kitobga kiritilgan dori-darmon va tashabbus turlariga qarab, umumiy savdo hajmining 10% dan 20% gacha. Biroq, Xitoyning eng yuqori darajadagi kompaniyalarida sotish G'arb kompaniyalariga qaraganda tezroq o'sib bormoqda.

Kelajakdagi o'sish

Xitoy dunyodagi ikkinchi yirik davlatdir retsept bo'yicha dori farmatsevtika bozorini tadqiq qiluvchi firma tomonidan chiqarilgan hisobotga ko'ra IMS Health. Hisobotda aytilishicha, Xitoyning farmatsevtika daromadi tez o'sib bormoqda va u erdagi bozor 2013 yilga kelib ikki baravar ko'payishi mumkin. Xitoyda retsept bo'yicha sotiladigan dori-darmonlarni sotish 2013 yilga qadar 40 milliard dollarga o'sadi. Xitoy tomonidan chiqarilgan farmatsevtika sanoatining qo'shilgan qiymat mahsuloti 2009 yilga nisbatan 14,9 foizga o'sdi Sanoat va axborot texnologiyalari vazirligi. O'tgan yilning 11 oyida tibbiyot sohasining umumiy foydasi 89,6 mlrd RMBni tashkil etdi, bu o'tgan yilga nisbatan 25,9% ga ko'pdir. Bu davrda o'sish yanvar-avgust oylarida atigi 16,2 foizni tashkil etdi.^[5]

Umumiy nuqtai

Xitoy a farmatsevtika sanoati tuzilishi va dunyodagi eng yirik farmatsevtika ishlab chiqaruvchilardan biriga aylandi. So'nggi bir necha o'n yilliklar davomida Xitoy farmatsevtika sanoati o'rtacha yillik o'sish sur'ati 16,72 foizni tashkil qilmoqda. Shu bilan birga, sanoat hali ham tarqoq geografik joylashuvi, takrorlanadigan ishlab chiqarish jarayonlari va eskirgan ishlab chiqarish texnologiyasi va boshqaruv tuzilmalari bilan kichik hajmga ega. Xitoy farmatsevtika sanoati ham bozor kontsentratsiyasining pastligi va xalqaro savdo raqobatbardoshligining zaifligi, shu bilan birga patentlangan mahalliy ishlab chiqarilgan farmatsevtika etishmasligi bilan ajralib turadi. (Barnet Siu; 2010)

Xitoyda investitsiya sharoitlari juda kengligi tufayli yaxshilandi iste'molchilar talabi uchun farmatsevtika, pastki mehnat xarajatlar va natijada yuzaga keladigan o'zgarishlar iqtisodiy islohot. Ga o'zgartirishlar patentlash talablariga to'liq mos keladigan qonunlar Intellektual mulk huquqining savdo bilan bog'liq jihatlari to'g'risida bitim (yoki "TRIPS shartnomasi") va Xitoy farmatsevtika bo'yicha ilmiy-tadqiqot ishlarining etishmasligi ham bozordagi bo'shliqlarni qoldirdi.

Mahalliy farmatsevtika sanoati mamlakatning ajoyib iqtisodiy o'sishiga muhim hissa qo'shdi. Farmatsevtika dunyodagi eng yirik ishlab chiqaruvchilardan biri sifatida ushbu tarmoq 1978 yildan 2003 yilgacha yillik birikma o'sish sur'atlariga 16,7 foizni tashkil etdi. Ikkalasi ham dunyoning boshqa iqtisodiyotlaridan ancha yuqori bo'lib, Xitoyni dunyodagi eng tez rivojlanayotgan farmatsevtika bozoriga aylantirdi. Garchi Xitoy farmatsevtika ishlab chiqarish va tarqatish uchun keng bozorning afzalliklaridan foydalangan bo'lsa-da, sanoat minimal innovatsiyalar va ilmiy-tadqiqot ishlari va yangi mahsulotlarni ishlab chiqarishga sarmoyadan aziyat chekmoqda. Sektorning miqyosi iqtisodiga hali erishilmagan. Farmatsevtika sanoatining aksariyat mahalliy ishlab chiqaruvchilari o'zlarining tovar mahsulotlarini ishlab chiqish uchun avtonom intellektual mulk va moliyaviy resurslarga ega emaslar. Aksariyat ishlab chiqaruvchilar past qo'shilgan qiymatli farmatsevtika va taqlid dori-darmonlarini takroriy ishlab chiqarishga ishonadilar.^[6]

Sifat

Xitoy farmatsevtika kompaniyalari tomonidan ishlab chiqarilgan dori-darmonlarning sifati va faol farmatsevtika tarkibiy qismlari (API) ko'pincha yomon.

So'nggi 2015–2017 yillarda Xitoyning farmatsevtika kompaniyalariga ma'lumotlar yaxlitligi bilan bog'liq jiddiy muammolarni, shu jumladan ma'lumotlarni yo'q qilish yoki manipulyatsiya qilish yoki test natijalarini ishlab chiqarishni keltirib chiqaradigan 35 ta FDA ogohlantiruvchi maktubi bo'lgan, qarang "Ma'lumotlarning yaxlitligi to'g'risida 2017 FDA ogohlantiruvchi xatlari tahlili" Barbara Unger, Unger Consulting Inc.https://www.pharmaceuticalonline.com/doc/an-analysis-of-fda-warning-letters-on-data-integrity-0003

Yaxshi ishlab chiqarish tartib-qoidalariga jiddiy rioya qilmaslik sababli FDA tomonidan Import Alert-ga joylashtirilgan Xitoy farmatsevtika kompaniyalarining uzoq ro'yxatiga qarang. http://www.accessdata.fda.gov/cms_ia/importalert_189.html

Yaxshi ishlab chiqarish tartib-qoidalariga jiddiy mos kelmasligini aniqlagan kompaniyalar tekshiruvlari asosida Evropa tibbiyot agentligi EudaGMDP nomuvofiqlik to'g'risidagi hisobotga qarang:http://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do

Yaxshi ishlab chiqarish tartib-qoidalariga jiddiy mos kelmasligi haqida FDA ogohlantirish xatlariga qarang: https://www.fda.gov/iceci/enforcactions/WarningLetters/default.htm

Tuzilishi va tendentsiyalari

Hozirda Xitoyda 3500 ga yaqin giyohvand moddalar ishlab chiqaruvchi kompaniya mavjud bo'lib, ular hukumat ma'lumotlariga ko'ra 2004 yildagi 5000 dan oshgan.^{[iqtibos kerak ]} Ularning soni yana kamayishi kutilmoqda. Mahalliy kompaniyalar 10 milliard dollarlik bozorda ustun etakchisiz raqobatlashadi. 2007 yilga kelib, Xitoy dunyodagi to'qqizinchi dori bozori bo'lib, 2008 yilda u sakkizinchi yirik bozorga aylanadi.

Business China ma'lumotlariga ko'ra, Xitoyning minglab mahalliy kompaniyalari bozorning 70 foizini va eng yaxshi 10 ta kompaniyaning 20 foizini tashkil qiladi. Aksincha, aksariyat rivojlangan mamlakatlarning eng yaxshi 10 kompaniyasi bozorning yarmiga yaqinini nazorat qiladi. 2004 yil 30 iyundan boshlab Davlat oziq-ovqat va farmatsevtika idorasi (SFDA) yangisiga javob bermaydigan ishlab chiqaruvchilarni yopmoqda GMP standartlar. Chet ellik o'yinchilar hisob-kitobga kiritilgan dori-darmon va tashabbus turlariga qarab, umumiy savdo hajmining 10% dan 20% gacha. Ammo yuqori darajadagi savdo Xitoy kompaniyalari IMS Health Inc ma'lumotlariga ko'ra G'arbnikiga qaraganda tezroq o'smoqda.^{[iqtibos kerak ]}

Hatto eng ko'p sotiladigan kompaniyalar ham 100 million dollarlik sotuvdan oshmaydi (kasalxona bozor). Xitoylik dori-darmon ishlab chiqaruvchilarning aksariyati 20-o'rinni egallab turibdi, ammo eng yaxshi 50 ta kompaniyaning 30 tasi mahalliy kompaniyalardir.^{[iqtibos kerak ]}

Bundan tashqari, Xitoy retseptsiz sotiladigan bozor tez sur'atlarda o'sib bormoqda va dunyodagi eng yirik to'rtinchi OTC bozoriga aylandi. Xorijiy korxonalar kengayib borayotgan birjadan tashqari bozorni diqqat bilan kuzatib borishdi. Merck 2003 yil sentyabr oyida Xitoyda OTC dasturini ishga tushirish to'g'risida e'lon qildi. Roche Keyingi besh yil ichida birjadan tashqari dori-darmon savdosini 50 foizga oshirish va 2008 yilda 1,3 milliardga etkazish maqsadida Xitoyni 10 ta asosiy birjadan tashqari bozorlardan biri sifatida qayd etdi. Novartis birjadan tashqari bozor ulushini Xitoyda kengaytirmoqda va Vayt birjadan tashqari bozorga chiqdi.

Xitoydagi farmatsevtika bozorida uning markasizligi ustunlik qiladi umumiy asosiy texnologiya va oddiy ishlab chiqarish usullari bilan ishlaydigan sanoat. Mahalliy farmatsevtika g'arbiy mahsulotlar kabi texnologik jihatdan rivojlangan emas, ammo shunga qaramay Xitoy bozorining taxminan 70 foizini egallaydi. Mahalliy kompaniyalar asosan hukumat tasarrufida bo'lib, ortiqcha ishlab chiqarish va zararlar bilan to'la. Xitoy hukumati xorijiy korporatsiyalar bilan raqobatlashish maqsadida sanoatni birlashtirish va yangilashni boshladi.

Bu eng ko'p deb taxmin qilinadi kasalxonalar o'z daromadlarining 25-60 foizini retsept bo'yicha sotishdan olishadi, kasalxonalar Xitoyda farmatsevtika mahsulotlarini tarqatadigan asosiy savdo nuqtalari bo'lib qolmoqda. Bu ajralib chiqishi bilan o'zgaradi shifoxona dorixonalari sog'liqni saqlash xizmatlari va chakana dorixona punktlari sonining ko'payishi bilan. Chakana savdo Hukumat nihoyat dori-darmonlarni birjadan tashqari mahsulotlarga ajratish tizimini joriy qilganidan so'ng, dorixonalar soni ko'payishi kutilmoqda. Hozirda hukumat zanjirli dorixonalarni rivojlantirishni rag'batlantirmoqda, ammo bir necha yil davomida uning samarasi sezilmasligi mumkin.

Farmatsevtika mahsulotlarining narxi doimiy ravishda pasayishda davom etadi. 2004 yil iyun oyida 400 narxi antibiotiklar 24 toifada, shu jumladan penitsillin, o'rtacha 35% ga kamaydi. Ushbu pasayishdan ta'sirlangan umumiy qiymat 42 million AQSh dollarini tashkil etdi. Markaziy hukumat farmatsevtika narxlarini qayta tuzishda muhim rol o'ynamoqda. Hukumat 2016 yildan beri so'nggi 20 yil ichida aksariyat dori vositalarining narxini majburan va doimiy ravishda 32 baravar pasaytirib yubordi.^[7] Kelgusi narxlarning pasayishi kasalxonalarning farmatsevtika chakana savdo do'konlaridan kelib chiqadi.

Qishloq farmatsevtika bozori sezilarli darajada o'zgaradi.^{[iqtibos kerak ]} 80% qalbaki mahsulotlar iste'mol qilinadi qishloq maydonlar.^{[iqtibos kerak ]} Bu juda katta imkoniyat yaratadi farmatsevtika kompaniyalari qishloq joylarda bozorni rivojlantirish. 2005 yilda Huanan farmatsevtika guruhi, Guanchjou Ruobei Xuale, Baiyunshan farmatsevtika guruhi va boshqalar qishloq bozoriga yo'naltirilgan harakatlarni kuchaytirdilar.^{[iqtibos kerak ]}

Xitoy farmatsevtika uskunalari sanoati 2015 yilgi bozor tadqiqotlari hisoboti farmatsevtika uskunalari sanoatining hozirgi holati bo'yicha professional va chuqur o'rganishdir.^[8]

Tarixiy xorijiy ishtirok

Bayer Germaniyaning ixtirochisi aspirin, 1882 yildayoq Xitoy bilan savdoni boshladi. Hoechst AG sifatida tanilgan Aventis, 1887 yilda o'z mahsulotlarini Xitoy bo'ylab 128 ta tarqatuvchi agentlar orqali sotgan va Xitoyning no. 1 G'arb tibbiyoti va bo'yoqlarni etkazib beruvchi. Eli Lilly va Kompaniya birinchi chet elda vakolatxonasini ochdi Shanxay 1918 yilda ICI, dunyodagi no. 3 farmatsevtika korxonasi AstraZeneca, 1898 yilda Xitoy bilan savdoni boshladi.

Ishlab chiqarish darajasi

2004 yilning yanvaridan sentyabrigacha bo'lgan 9 oy ichida mamlakat farmatsevtika sanoatining umumiy mahsulot ishlab chiqarish hajmi 40 mlrd. Dollarni tashkil etdi, bu 2003 yilning shu davriga nisbatan 15,8% ga ko'pdir. Shu davrda 23 asosiy davlatga tegishli farmatsevtika kompaniyalari 10 milliard dollarlik savdoga ega edi. 16 ta odatdagi shahar kasalxonalarida o'tkazilgan so'rovda, giyohvand moddalarni iste'mol qilish 2004 yil birinchi yarmida 2003 yilga nisbatan 32,23% ga oshdi.

Xitoyning barcha farmatsevtika korxonalarining 36 foizga yaqini davlatga tegishli. Yana 35% xususiy mahalliy korxonalar va qolgan 29% chet el mablag'lari hisobidan tashkil etilgan. Sintetik dori ishlab chiqarish Xitoyda farmatsevtika sanoatining eng yirik biznesi bo'lib qolmoqda va sanoat sotuvlarining 65 foizini tashkil etadi. Sanoat savdosining yana 21 foizi ushbu mahsulotga to'g'ri keladi an'anaviy xitoy tibbiyoti. Biotexnika - tegishli tibbiy mahsulotlar va tibbiy asbob-uskunalar qolgan qismini tashkil eting.

Mintaqaviy tarqatish

Xitoyning ulkan va asta-sekin qarib borayotgan aholisi va kuchli biofarmatsevtika sektori deyarli katta, ammo xilma-xil farmatsevtika bozori profilini kafolatladi. Chjetszyan, Guandun, Shanxay, Tszansu va Xebey provinsiyalar har doim Xitoyning eng samarali viloyatlari beshligiga kirgan. Ushbu viloyatlarning har biri 1998 yildan 2003 yilgacha o'rtacha yillik 20 foizga o'sib bordi (1998 va 1999 yillarda Tszantsudan tashqari) va Xitoy farmatsevtika sanoatida tobora sog'lom rivojlanib borayotgan tendentsiyani aks ettiradi.

Farmatsevtika firmalarining aksariyati janubi-sharqiy zonada joylashgan bo'lib, ular ikkita rivojlangan hudud va uchta rivojlanmagan hududlarni o'z ichiga oladi. Rivojlangan farmatsevtika sanoatining o'sish ustunlari deb nomlangan ikkita eng mashhur yo'nalishlari Sharqiy Xitoy uning zonasi Chjetszyan viloyat markazda va joylashgan Janubiy Xitoy bilan ifodalanadigan zona Guandun viloyat. Ushbu ikki viloyatning umumiy ishlab chiqarish qiymati 2003 yilda Xitoyning farmatsevtika sanoatining umumiy ishlab chiqarish qiymatining 21 foizini tashkil etdi.

Farmasevtika sanoatining potentsial nuqtalari deb nomlangan uchta rivojlangan yo'nalishi, shuningdek, markazlashgan Xitoy mintaqasi, shimoli-sharqiy zonasi va janubi-g'arbiy zonasi deb nomlanadi. Xebey Viloyat, Heilongjiang viloyat va Sichuan navbati bilan viloyat.

Xitoyda farmatsevtika sanoatining rivojlanishi asosan iqtisodiy omillar ta'sirida ekanligi aniqlandi. Sanoat mintaqasining tabiati taxminan quyidagi uch turga kirishi mumkin: tabiiy resurs - boshqariladigan mintaqa, iqtisodiyotga asoslangan mintaqa va fan va texnologiyalarga asoslangan mintaqa. Xitoyda farmatsevtika sanoati boy tabiiy resurslarga yoki ilg'or ilm-fan va texnologiyalarga ega mintaqalarda emas, balki faqat kuchli makroiqtisodiy asoslarga ega bo'lgan hududlarda yaxshi rivojlanadi. Bundan tashqari, makroiqtisodiyot qanchalik kuchli bo'lsa, farmatsevtika sanoati tezroq rivojlanib borishi ko'rsatilgan. Shuning uchun mintaqada farmatsevtika rivojlanishiga oid qarorlarni qabul qilish siyosati asosan uning makroiqtisodiy holatiga asoslangan bo'lishi kerak.

Keng ma'noda, Xitoyda farmatsevtika sanoatining dinamik xususiyatlari barqaror bo'lib qolmoqda. Islohotlar rejasiga ko'ra, Xitoy giyohvand moddalarni nazorat qilish va boshqarish bo'limlarida vertikal boshqarish rejimini olib boradi, dori vositalari ustidan nazorat va nazoratni kuchaytiradi va asta-sekin yuridik menejment, yagona huquqni muhofaza qilish organlari, odob-axloq qoidalari, halollikni o'z ichiga olgan giyohvand moddalarni boshqarish tizimini yo'lga qo'yadi. amaliyot va yuqori samaradorlik. Dori-darmonlarni qabul qilishning ob'ektiv talablari va tibbiy xizmatni rivojlantirish ehtiyojlarini qondirish uchun 1998 yilda giyohvand moddalarni nazorat qilish va boshqarish organi tashkil etildi.

Xitoyda farmatsevtika sanoati juda ko'p qismlarga bo'linganligi aniqlandi. Viloyat farmatsevtika sanoatining haddan tashqari takroriy tashkil etilishi Xitoyning boshqa tarmoqlariga nisbatan jiddiy ekanligi aniqlandi. Bu shuningdek, Xitoyning turli mintaqalarida farmatsevtika sanoatining past darajadagi, takrorlanadigan rivojlanish holatini namoyish etadi.

Hozirda Xitoyda farmatsevtika sanoati hali ham rivojlanib bormoqda. Shuning uchun mintaqaviy farmatsevtika sanoatiga diqqatni jamlash eng maqbul strategiyadir. Ushbu strategiyaning uchta asosiy sababi bor: farmatsevtika sanoatining yuqori rentabelligi va o'sishi, mintaqalar o'rtasida keraksiz siyosiy raqobat va mintaqaviy ma'muriy hokimiyatning haddan tashqari ekspluatatsiyasi. (Xu Yuanjia; 2007)

Farmatsevtika sanoati har doim yuqori rentabellik va tez sur'atlar bilan rivojlanib borayotgan soha sifatida tanilgan. Xitoy bozori isloh qilingandan so'ng, Xitoy asta-sekin sog'lom, barqaror va tez rivojlanayotgan farmatsevtika sanoati uchun bo'sh joy yaratmoqda, bu erda foyda darajasi va o'sish sur'ati boshqa sohalarga qaraganda ancha yuqori. Yuqori foyda keltiradigan daromadlarni hisobga olgan holda, mintaqaviy hukumatlar mintaqaviy raqobatbardoshlikni, haqiqiy afzalliklarni va rivojlanish strategiyasini sinchkovlik bilan tahlil qilmasdan, mintaqaviy tibbiyot sanoatining haddan tashqari rivojlanishiga yo'l qo'yadilar. rag'batlantirish butun iqtisodiyotning mintaqaviy rivojlanishi.

Xitoyda giyohvand moddalarni boshqarish bo'limlari markaziy va mintaqaviy hukumat darajasida tashkil etilgan. Har bir mintaqada ma'lum bir vakolat va kuchga ega bo'lgan mintaqaviy giyohvand moddalarni boshqarish bo'limi mavjud. Ma'muriyat bo'limi o'rtasida yaxshi aloqa va hamkorlik bo'lmasa, mintaqalar o'rtasida keraksiz raqobat paydo bo'lishi mumkin. Har bir ma'muriy bo'limga qarashli giyohvand moddalar ishlab chiqaradigan kompaniyalar soni ko'pincha noto'g'ri qayd etilib, natijada mintaqaviy iqtisodiy rivojlanish va hukumat faoliyatining baholash ko'rsatkichi noto'g'ri.

Murakkab tartibga solish jarayonlari mintaqaviy ma'muriy hokimiyatning haddan tashqari ekspluatatsiyasini keltirib chiqaradi. 2001 yilda Xitoy farmatsevtika to'g'risidagi qonuni qayta ko'rib chiqilgunga qadar viloyat dori ma'muriyatiga ro'yxatdan o'tish jarayonini soddalashtirish vakolati berilgan edi. umumiy dori. Binobarin, ushbu mintaqaviy hokimiyat vakolatidan foydalanilib, bir xil dori-darmonlarning haddan tashqari ko'payishiga olib keldi. Masalan, a ftorxinolon 1000 dan ortiq korxona tomonidan ro'yxatdan o'tgan va ishlab chiqarilgan dori turi. Yaxshiyamki, Xitoy hukumati jiddiy muammoni darhol anglab etdi va hokimiyatning takrorlanishiga yo'l qo'ymaslik uchun mintaqaviy hokimiyatni tortib oldi. Ammo preparatning takrorlanishi bu yagona misol emas. Bir necha yil oldin dori-darmon ishlab chiqaradigan korxonalarni ochish huquqini berish huquqi viloyat darajasiga tushirilgandan so'ng, giyohvand moddalar ishlab chiqaradigan kompaniyalar sonining keskin o'sishi qayd etildi. 2003 yil birinchi yarmida 70 ta yangi dori ishlab chiqaruvchi korxona ochilishi tasdiqlangan bo'lsa, 1998 yildan 2001 yilgacha bo'lgan uch yil ichida faqatgina 45 ta shu kabi korxona ochilishi ma'qullandi.

Tadqiqot va rivojlantirish

Ularning kam byudjeti bilan tadqiqot va rivojlantirish, Xitoyning farmatsevtika ishlab chiqaruvchilari boshqa ligada ko'p millatli, lekin ular ma'lum afzalliklarga ega. Ko'pgina Xitoy kompaniyalari nafaqat ishlab chiqaradi dozalash shakllari (masalan, planshetlar), shuningdek, o'zlariga tegishli dorixonalar ular qayerda? tarqatilgan, shuningdek, ularni dori-darmonlarning qariyb 80% sotiladigan kasalxonalarga etkazib beradigan tarqatish tarmoqlari. Bundan tashqari, xitoylik kompaniyalar ishlab chiqarishi mumkin umumiy markali dorilarning versiyalari, ularning narxining bir qismiga.

1950 yildan buyon Xitoyda ishlab chiqarilgan 3000 ta farmatsevtika, shu jumladan an'anaviy dori-darmonlarni hisobga olmaganda, Xitoyning deyarli 90 foizi singari, 99 foizi xorijiy mahsulotlarning nusxalari. biotexnologiya mahsulotlar. Ko'pgina Xitoy kompaniyalari - hatto qo'shma korxonalar - bir xil genericlar uchun o'zaro raqobatlashish. Ko'pchilik tirik qolish uchun kurashmoqda; Farmatsevtika departamenti ma'lumotlariga ko'ra 1999 yilda 32 foizdan ko'p zarar qayd etilgan Milliy taraqqiyot va islohotlar komissiyasi.

Bundan tashqari, xalqaro farmatsevtika gigantlari bilan taqqoslaganda, Xitoy kompaniyalari nafaqat kichik, balki zaif hamdir texnologiya va ko'pincha etishmayapti poytaxt. Xitoyga tegishli bo'lgan ilmiy-tadqiqot ishlarining umumiy xarajatlari farmatsevtika korxonalar G'arbning yagona yirik farmatsevtika kompaniyasi sarflagan mablag'dan kamroqni tashkil etdi.

Hozirgi vaqtda Xitoyda 5000 dan ortiq ilmiy-tadqiqot va tajriba-konstruktorlik institutlari mavjud, ammo ularning ozgina qismigina ma'lum sohalarda xalqaro miqyosda raqobatlashishga qodir.

Ilmiy-tadqiqot tizimi ixtisoslashgan ilmiy-tadqiqot institutlari, yirik universitetlar, biotexnologiya kompaniyalari va yirik farmatsevtika korxonalarining ilmiy-tadqiqot bo'limlaridan iborat. So'nggi yillarda o'rta va kichik o'lchamli biotexnologiya kompaniyalar tez sur'atlar bilan rivojlanmoqda. Hozirgi kunda mamlakat miqyosida 1000 dan ortiq bunday sub'ektlar mavjud va ularning 30% dan ortig'i xususiy mulkdir. Ushbu turni targ'ib qilish uchun maxsus hukumat mablag'lari mavjud tadbirkorlik.

So'nggi bir necha yil ichida ba'zi xitoylik farmatsevtika kompaniyalari asosan ichki o'sish ehtiyojlari tufayli ilmiy-tadqiqot infratuzilmasini yaratishni boshladilar, ammo ularning asosiy yo'nalishi mavjud texnologiyalarni takomillashtirishga yoki rivojlantirishga qaratilgan yangi dorilarning umumiy versiyasi.

Xitoyda tadqiqot ishlarini kengaytirish uchun kompaniyalar orasida GlaxoSmithKline,^[9] Bayer,^[10] Bristol-Mayers Squibb,^[11] Merck & Co^[12] va Eli Lilly & Company.^[13]

Xitoy va G'arb farmatsevtika kompaniyalarini taqqoslash

AQSh va Evropadagi hamkasblari singari, xitoylik farmatsevtika biznesi davlat idoralari tomonidan tartibga solinadi va biznesda raqobat kuchli. Eng katta farqlarga quyidagilar kiradi:

• aksariyat xitoylik farmatsevtika kompaniyalari umumiy dori ishlab chiqaruvchilar;
• katta raqam an'anaviy xitoy tibbiyoti ishlab chiqaruvchilar;
• kasalxonalar hali ham dori vositalarining asosiy bozori;
• Patent masalalar xitoylik ishlab chiqaruvchilarning eng katta zaifligi.

Xitoylar rivojlanayotgan paytda API ular orqali patent qidiruvlarini sinab ko'rishadi Internet, ammo mavjud xizmatlarning ko'lami bilan cheklangan. Hali ham ozgina fabrikalarda xodimlarning patent vakillari bor, ammo yirik G'arb firmalari bilan hamkorlik qilishni istagan yirik farmatsevtika guruhlari uchun bu tez orada bo'lishi mumkin.^[14]

Xitoyning ishbilarmonlik muhiti asosan munosabatlarga asoslangan bo'lib, bu farmatsevtika biznesida aks etadi. Shaxsiy aloqalar orqali farmatsevtika kompaniyalari bilan aloqalarni o'rnatish - bu Xitoy farmatsevtika kompaniyalari bilan bog'lanishning keng tarqalgan usuli. Farmatsevtika ko'rgazmalarida, farmatsevtika konferentsiyalarida yoki seminarlarda qatnashish - bu tegishli davlat idoralari yoki assotsiatsiyalari rasmiylari va farmatsevtika bo'yicha katta rahbarlar ishtirokidagi matbuot anjumanini o'tkazish kabi yana bir yondashuv.^[14]

Mahalliy kompaniyalar

2003 yildan 2004 yilgacha dorixonalar soni 180 mingdan 200 mingtaga ko'tarildi va tarmoq do'konlariga egalik qiluvchi chakana sotuvchilar soni 1200 dan 1349 gacha ko'tarildi.

1980-yillarga qadar Xitoyning tarqatish kanali dorixona mahsulotlar edi vertikal ravishda birlashtirilgan, ozgina bo'lgani kabi vositachilar uchun Dori savdo va yagona ulgurji savdogarlar edi an'anaviy dorixona do'konlari. Biroq, 1980-yillardan so'ng, Xitoyda islohotlarning chuqurlashishi bilan, Xitoyning dorixona mahsulotlarini tarqatish chuqur o'zgarishlarga duch keldi va buni ma'lum darajada o'zgartirdi.

Hozirgi vaqtda Xitoyning dorixona korxonalari uchun uchta asosiy tarqatish kanali mavjud:

• Dorixona korxonalari - milliy bosh agent - ulgurji sotuvchi - chakana sotuvchilar - bemorlar

Ushbu tarqatish shakli bo'yicha mamlakatda dorixona kompaniyasining bir yoki bir nechta mahsulotini sotish uchun mas'ul bo'lgan yagona vakolatli tashkilot mavjud. Bunday tarqatishni "milliy agent rejimi" deb ham atash mumkin. Dorixona kompaniyasi mahsulotlarni ishlab chiqarish, tadqiq etish va rivojlantirish uchun mas'uldir va kompaniya mahsulotlarini mamlakat bo'ylab sotish uchun bosh agent. 2010 yilgacha materikda asosan uchta milliy distribyutorlik agentligi mavjud edi: Sinopharm Group, Shanghai Pharma va CR Pharmaceutical. Ko'pgina hollarda, agentlar dorixona mahsulotlarini xarajatlar va foydani tortib ko'rgandan so'ng naqd pul bilan sotib olishadi va bozor xavfi ulgurji savdogarlarga tegishli.

• Dorixona korxonalari - mintaqaviy umumiy agentlar (subteklgiler) - chakana sotuvchilar - bemorlar

Ushbu rejim asosida dorixona korxonasi o'z milliy yoki mintaqaviy bosh agentini qidiradi va o'z mahsulotlarini sotish uchun agentning bozor tarmog'idan foydalanadi. Bunday tarqatish rejimini "mintaqaviy umumiy agent rejimi" deb atash mumkin. Dorixona korxonasi odatda o'zining bosh agentiga mahsulotlarini sotish yoki savdo vositasi bilan savdo qilish orqali ishonib topshiradi yoki agent bilan ittifoq tuzib, mahsulotni arzon narxda taqdim etadi. Agent, ma'lum miqdordagi mahsulotni sotib olgandan so'ng, dorixona kompaniyasidan ma'lum bir mintaqada sotish uchun ruxsatni qo'lga kiritadi va uning mintaqadagi yagona vakolatli agentiga aylanadi. Mintaqaviy bosh agent - katta mintaqadagi umumiy ulgurji sotuvchi, viloyat ulgurji savdogari, tuman ulgurji savdosi va hokazo bo'lishi mumkin. Katta mintaqada yoki viloyatda mintaqaviy bosh agentlar bemorlarni o'zlarining mahsulotlarini subtek va chakana savdo do'konlari orqali ta'minlaydilar. Tuman kabi kichik joyda, mahsulotlar to'g'ridan-to'g'ri mintaqaviy bosh agentdan chakana sotuvchilarga, so'ngra bemorlarga ulgurji savdogarlar ishtirokisiz o'tishi mumkin.

• Dorixona korxonalarining marketing kompaniyalari - dorixona kompaniyalari mahalliy ofislari - chakana sotuvchilar - bemorlar

Bunday tarqatish kanalini olishdan oldin dorixona korxonasi avval mustaqil litsenziyaga ega marketing kompaniyasini ro'yxatdan o'tkazishi kerak, so'ngra yirik shaharlarda o'z mahsulotlarini o'z mintaqalarida sotilishi va tarqatilishini nazorat qilish uchun mas'ul bo'lgan vakolatxonalarini ochishi kerak. Dorixona korxonasi uchun katta miqdordagi kapital va yuqori darajadagi boshqaruvni talab qiladigan bunday tarqatish rejimi asosan yirik dorixona korxonalari tomonidan qo'llaniladi.

Yuqorida aytib o'tilgan rejimlarda dorixona korxonalari, vositachilar va bemorlar uchta asosiy komponent hisoblanadi. Dilerlar, shuningdek, ulgurji va chakana savdo toifalari bo'yicha tasniflanishi mumkin. Chakana savdo do'konlari, do'konlari va chakana savdo guruhlari bo'lmagan do'konlarni o'z ichiga oladi. Shuni ta'kidlash kerakki, Xitoyda eng katta dorixona sotuvchisi kasalxonadir, chunki bu mamlakat tibbiyoti va ijtimoiy ta'minot mexanizmlari. Chakana savdo bozorida dorixona mahsulotlarining 85% kasalxonaga kasalxonaga yuboriladi.

Shunday qilib, Xitoyda asosiy tarqatish kanallarini quyidagicha ta'riflash mumkin:

• dorixona korxonalari - kasalxonalar-bemorlar; dorixona korxonalari - ulgurji savdogarlar - kasalxonalar - bemorlar;
• dorixona korxonalari - agentlar - ulgurji savdogarlar - chakana sotuvchilar - bemorlar;
• dorixona korxonalari - chakana sotuvchilar - bemorlar.

Dastlabki ikkita rejim Xitoyda etakchi hisoblanadi.

So'nggi yillarda Xitoyning dorixona korxonalari ikkita yangi sohaga kirishdilar: elektron biznes va sozlash dorixona chakana savdo do'konlari. Hozirgi vaqtda Xitoyda dorixona biznesining B dan S rejimiga o'tishi cheklangan.

B2B Xitoyning elektron dorixona tijoratining asosiy rivojlanish tendentsiyasidir. B2B elektron dorixona biznesining savdo hajmi umumiy dorixona savdosining atigi foizini tashkil etsa-da, u hali ham katta rivojlanish salohiyatiga ega. Xitoyda B2B elektron dorixona savdosi yiliga 300 foizga o'sdi. 2003 yilda Internet-dorixona savdosi hajmi umumiy hajmning 10 foizini tashkil etdi.

Bundan tashqari, tobora ko'proq IT va boshqa sohalarda etakchi kompaniyalar o'zlarining investitsiyalarini farmatsevtika sanoatiga yo'naltirmoqdalar. Birgina misol - Fang Zheng Group, farmatsevtika va sog'liqni saqlashga jami 363 million dollar sarmoya kiritgan IT-kompaniya. Guanchjou Bai Yun Shan farmatsevtika fabrikasi 12 million AQSh dollar miqdorida mablag 'ajratib, tashqi foydalanish bo'yicha dori-darmonlarni ishlab chiqarishni boshladi, bu esa 48 million dollarlik antibiotiklar loyihasidan tashqari.

Ilmiy-tadqiqot ishlarini olib borayotgan mahalliy kompaniyalar

Bugungi kunga kelib, Xitoyning mahalliy farmatsevtika sanoati juda kam sarmoya kiritdi tadqiqot va rivojlantirish ammo yangi dorilar markaziy hukumat orqali ilmiy-tadqiqot ishlarini rag'batlantirmoqda sarmoya va boshqalar rag'batlantirish jahon standartidagi farmatsevtika sanoatini barpo etish maqsadida.

• C & O farmatsevtika texnologiyalari xoldingi Ltd (SIN: COPT) - bu Xitoyning barcha hududlarida 3000 dan ortiq distribyutorlar va 300000 klinikalar, dorixonalar va shifoxonalarni qamrab olgan keng tarqatish tarmog'iga ega bo'lgan Xitoyda joylashgan farmatsevtika guruhi. Xususiy dori vositalarining portfelini kengaytirish uchun kompaniya infeksiya, HBV, saraton, sil kasalligi, qarish va semirishga qarshi o'tkir tibbiy yo'nalishlarga murojaat qiladigan bir qator dori vositalarini ishlab chiqarmoqda. Shuningdek, 1-toifadagi uchta potentsial dori ishlab chiqilmoqda: Gepatit B ga qarshi preparat, yangi immuno-kuchaytiruvchi va saraton kasalligini davolash uchun muqobil dori va keng ko'lamli bakterial patogenlarga, ayniqsa Gram-pozitivga nisbatan samaraliroq bo'lgan antibiotik preparati. dorilarga chidamli bakteriyalar. Kimyoviy sintez, dori-darmonlarni shakllantirish va tayyorlash usullaridan tortib klinik tadqiqotlar, mahsulotlarni ro'yxatdan o'tkazish, ishlab chiqarish texnikasi va farmatsevtika tahliliga qadar turli sohalardagi mutaxassisliklari bo'yicha tanlab olingan 80 ta tadqiqotchi bilan C&O bir nechta malakali farmatsevtika kompaniyalaridan biri hisoblanadi. Xitoy o'zlarining ilmiy-tadqiqot ishlarini Xitoyga topshirmoqchi bo'lgan tobora ko'payib borayotgan xalqaro farmatsevtika kompaniyalariga kontrakt tadqiqotlari xizmatlarini ko'rsatish bo'yicha tajribaga ega. C&O farmatsevtika kompaniyalariga Xitoyda ham, Xitoydan tashqarida ham kontrakt tadqiqotlari va shartnomaviy ishlab chiqarish xizmatlarini ko'rsatib kelmoqda.
• Jiangsu Hengrui Medicine Co.Ltd. (SHA: 600276), qarorgohi Tszianu provinsiyasining Lianyungang shahrida joylashgan bo'lib, Xitoyning etakchi farmatsevtika kompaniyalaridan biridir. Hengrui har doim ilmiy-tadqiqot ishlarini qadrlaydi va 1994 yildan beri Liangyugangda ilmiy-tadqiqot ishlarini olib boradi. 2000 va 2011 yillarda Shanxay ilmiy-tadqiqot markazi.^[15] va Chengdu ilmiy-tadqiqot markazi^[16] mos ravishda tashkil etildi. Xengruining AR-GE ishlab chiqarishga qo'ygan sarmoyasi yuqori bo'lib qolmoqda va ketma-ket Xitoyda so'nggi yillarda yuqori o'rinlarni egallab turibdi.^[17][18][19] Xengruining ilmiy-tadqiqot ishlari onkologiya, metabolik kasalliklar, yurak-qon tomir kasalliklari, yallig'lanish, markaziy asab tizimi va immun tizimidagi kasalliklar va boshqalarni o'z ichiga oladi va saratonga qarshi innovatsion dori vositalari bilan mashhur. Apatinib, masalan, Xitoy FDA (CFDA) tomonidan 2014 yil dekabr oyida ma'qullangan, dunyodagi rivojlangan oshqozon saratonini davolashga qaratilgan birinchi kichik molekula anti-angiogenezidir.^[20] Xengruining ilmiy-tadqiqot faoliyati chet ellarda kengayib bordi - AQSh, Yaponiya va Avstraliyada ilmiy-tadqiqot ishlari bo'yicha idoralar tashkil etildi va bir qator taniqli xalqaro farmatsevtika kompaniyalari va institutlari - Incyte,^[21] Tasoko^[22] va MD Anderson saraton markazi.^[23]
• Shijiazhuang Pharma Group: Asoslangan Shijiazhuang, poytaxt Xebey Xitoyning shimoli-sharqidagi provintsiya, farmatsevtlar guruhi Xitoyning eng yirik farmatsevtika sanoatidan biridir. 2004 yil noyabr oyida guruh o'zining tergov dori vositasini rasmiy ravishda ishga tushirganligini e'lon qildi butilftalid (NBP). Guruh sotib oldi patentlar Xitoy Tibbiyot fanlari akademiyasidan 4 million dollardan kam bo'lgan dori-darmon va atigi 6,3 million dollarga sarflangan klinik sinovlar. Shijiazhuang Pharma Group yangi dori ishlab chiqarishda juda xosdir. Kompaniya uchta usuldan foydalanadi: birinchidan, universitetlar va ilmiy-tadqiqot institutlari bilan hamkorlikda yangi dori vositalarini yaratish; ikkinchidan, patentlangan dori vositalarining patentlari amal qilish muddati tugashidan oldin umumiy giyohvandlik huquqlariga murojaat qilish; uchinchidan, an'anaviy xitoy dori-darmonlarini (TKM) modernizatsiya qilish, ya'ni kimyoviy dorilarni ishlab chiqarishda ishlatiladigan miqdordagi TKMlarni ishlab chiqarish. Uchinchi yo'l, selderey urug'idan olinadigan an'anaviy xitoy tibbiyoti - butilftalidni ishlab chiqarishda ishlatilgan.
• Wuxi Pharmatech: WuXi PharmaTech (Kayman), Inc., uning filiallari orqali, farmatsevtika va biotexnologiya tadqiqot va rivojlantirish autsorsing Xitoy Xalq Respublikasidagi kompaniya. U portfelini taqdim etadi laboratoriya va ishlab chiqarish xizmatlari giyohvand moddalarni kashf qilish va rivojlanish farmatsevtika va biotexnologiya kompaniyalariga jarayon. Bundan tashqari, WuXi PharmaTech xizmatlari jarayonlarni rivojlantirishni o'z ichiga oladi, masalan, jarayonni o'rganish va jarayonni optimallashtirish mijozlarga giyohvand moddalarga nomzodlarni ishlab chiqarishda yordam berish bo'yicha xizmatlar; va takomillashtirilgunga qadar dori moddasi bo'lgan ilg'or qidiruv mahsulotlarni ishlab chiqarish faol farmatsevtika tarkibiy qismlari. Nyu-York fond birjasida ro'yxatga olingan: ADR (NYSE) WX fond belgisi.
• Harbin farmatsevtika guruhi Co raqobatbardosh bo'lishga yaqin turibdi, ikkita xorijiy investor tomonidan 250 million dollar mablag 'sarflanishi rejalashtirilgan, Warburg Pincus Nyu-York va Citic Capital of Hong Kong. Ushbu mablag 'Xarbinga ilmiy-tadqiqot ishlarini kengaytirishga imkon beradi - kompaniya Arxeologik tadqiqotlar uchun daromadning taxminan 5 foizini sarflaydi, bu xitoylik dori ishlab chiqaruvchisi uchun istisno bo'lib, ko'p millatli kompaniyalar sarflagan mablag'larning atigi uchdan bir qismigacha - va konsolidatsiya sifatida yirtqich emas, balki uning yirtqich bo'lishiga yordam beradi. farmatsevtika sanoati shafqatsizroq bo'ladi.
• Sinovac Biotech Ltd (AMEX: SVA) yaqinda Bilive marketingini boshladi va 2005 yil may oyida o'zining birinchi sotuvlarini qayd etishni kutmoqda Gepatit A & B vaktsinasi. Bu xitoylik olimlar tomonidan ishlab chiqarilgan birinchi birlashtirilgan inaktiv Gepatit A & B vaktsinasi va bu vaksinada dunyoda faqat bitta to'g'ridan-to'g'ri raqobatdosh Gepatit A & B vaktsinasi mavjud, bu Xitoyda mavjud bo'lmagan va mamlakatlarda Bilive'dan ancha yuqori narxga sotiladigan GSK's Twinrix. qaerda sotiladi? 2004 yilda kompaniya taxminan 6,5 million dollarlik savdo qildi, bu 2003 yilgi savdolardan ikki baravar ko'p. Endi Sinovacda Xitoyda sotish uchun to'liq tasdiqlangan ikkita vaktsina mavjud. Hozirgi kunda u a rivojlanishida dunyoda etakchi hisoblanadi SARS emlash.
• Zensun (Shanxay) Sci & Tech Co., Ltd. xalqaro bozor talablarini yaxshi biladigan, innovatsiyalarga asoslangan yuqori foyda olish potentsialiga ega bo'lgan biotexnologik farmatsevtika kompaniyasi. O'ziga tegishli intellektual xususiyatlar orqali yangi dori-darmonlarni o'rganish va ishlab chiqishga bag'ishlangan. "Hayotni davolash" tamoyiliga rioya qilgan holda, Zensun uzoq vaqt davomida o'smalarga qarshi dorilar va yurak etishmovchiligiga qarshi dori-darmonlarni tadqiq qilishga e'tibor qaratmoqda. Innovatsion nazariya asosida Zensun ikkita dori vositasini muvaffaqiyatli ishlab chiqardi: Rekombinant inson neuregulin-1 in'ektsiyasi, yurak etishmovchiligiga qarshi dori va rekombinant inson ErbB3 fragmentli in'ektsiyasi, o'smalarga qarshi terapevtik emlash, ikkalasi ham klinik sinovlardan o'tgan. 2006 yilda Zensun (Shanxay) San-Diego shahrida (Kaliforniya) "Zensun" (AQSh), Inc sho''ba korxonasini yaratdi, bu hayajonli va yangi "Rekombinant inson neuregulin-1" (Neucardin) ning FDA hujjatlarini rasmiylashtirish, klinik sinovlari va tijoratlashtirish jarayonini boshqarish uchun. surunkali yurak etishmovchiligini davolash, shuningdek Zensun (Shanxay) tomonidan ishlab chiqilgan boshqa birikmalar. In 2009, Zensun (USA) was approved by the US FDA to conduct a Phase 2a US-based trial of Neucardin administration to subjects with NYHA Class II and III Chronic Heart Failure.
• Tonghua Dongbao Pharmaceuticals Ltd., founded in 1985, is a bio-tech pharmaceutical with headquarters, research and manufacturing facilities situated in China's Northern city of Tongxua. In 1998 Tonghua Dongbao became the 3rd company worldwide to successfully develop and manufacture its own recombinant human insulin line, Gansulin, for the treatment of Diabetes Mellitus. Its recombinant human insulin production base is the largest of its kind in Asia, producing both vials of insulin and insulin cartridges for the Gansulin Insulin Pen. The company is accelerating expansion into markets outside of China, currently exporting insulin and a variety of other medicines to over 10 countries.

Foreign expansion

Most Chinese pharma companies with foreign distribution export an'anaviy xitoy tibbiyoti asosan to Osiyo countries or regions. Their foreign distribution, therefore, is not as significant as their western counterparts.

The Chinese government legalized foreign ownership of retail pharmacies in 2003. On March 14, 2005, AXM Pharma Inc. (AMEX: AXJ) entered into a distribution agreement with Sinopharm Holding Guangzhou Co., Ltd. for an expected purchase amount through December 2005 of RMB 54 million ($6.56 million) for the company's line of Elegance products, formerly known as Whisper.

Additional products, including Anti-Fatigue and Asarone, are expected to be sold in upcoming quarters. The sales territory includes Guandun, Guansi, Yunnan, Guychjou, Fujian, Sichuan, Chontsin, Xaynan, Xubey va Xunan.

Sinopharm Holding Guangzhou Co., Ltd., an affiliate of Xitoy milliy farmatsevtika guruhi Corp. is actively engaged in the research and development, capital investment, manufacture and trade of pharmaceuticals and medical instruments. Sinopharm has achieved an annual sales volume of 10 billion RMB (over 1.2 billion U.S. Dollars) and a total import and export volume of 200 million U.S. Dollars.

Chet el kompaniyalari

In recent years, more and more western pharmaceutical corporations, such as Pfizer, GSK, Roche, Novo Nordisk, have set up commercial operations and R&D centers in China. Many world leading pharmaceutical companies have established Qo'shma korxona manufactories in China. Some have even set up sole propriety manufactories. As of 2004, amongst the largest 500 overseas enterprises, 14 of them are pharmaceutical companies.

As of 2004 (three years after China's WTO entry), nearly all global pharmaceutical companies have already completed their accession into the Chinese market and will gradually shift their focus to research development. The main reasons for overseas companies coming to China have been to save costs by using the extensive fan va texnika research bases currently in place in China, the abundant kadrlar bo'limi, and less expensive medical and klinik sinovlar.

Chet el ishlab chiqarishi

The involvement of many foreign pharmacy enterprises operating in China can be dated back to a century ago. Bayer of Germany, the inventor of aspirin, began trade with China in as early as 1882. Hoechst AG sifatida tanilgan Aventis, sold its products through 128 distribution agents across China in 1887, becoming China's No.1 Western medicine and dyeing provider. AQSh Eli Lilly & Co. opened its first overseas representative office in China's Shanghai in 1918. ICI, the predecessor of the world's No 3 pharmacy enterprise AstraZeneca, began trade with China in 1898, and still maintained its old-time office by the Huangpu River in Shanghai.

As of 2007, there were already 1,800 foreign-funded pharmaceutical enterprises in China [Reference: https://web.archive.org/web/20080513032052/http://www.pacificbridgemedical.com/publications/html/ChinaDec1998.htm ]. Currently, all the top 20 pharmaceutical companies in the world have set up qo'shma korxonalar or wholly owned facilities in China. This suggests that market conditions have never been more challenging, with competition at an all-time high.

• Pfizer produces and markets more than 40 innovative drugs in China, and the quality of its products all met the Chinese Pharmacopeia. Pfizer has GMP yilda ishlab chiqarish quvvatlari Dalian, Suzhou va Vuxi. Its Dalian facility, built in 1989 jointly with Dalian Pharmaceuticals was the first to get GMP certification in China. Pfizer has invested more than $500 million in China. Lastly, in 2012 Pfizer established a joint venture with Hisun Pharmaceuticals (Hisun 51% - Pfizer 49%) to market branded generics under the label Hisun-Pfizer.
• GlaxoSmithKline has more than 2000 employees in China, and its drugs are sold in 60 cities. The company mainly sells drugs treating HBV, asthmas and infections.
• Merck sells antibiotiklar, prostata drugs, yurak-qon tomir drugs, pain relievers, osteoporoz va vaksinalar. It set up its first joint venture in China in 1994.
• Novartis has invested about 100 million^{[tushuntirish kerak ]} in China, with four manufacturing facilities in Beijing and Shanghai (Changsu). Its core businesses involve patented drugs, generic drugs, eye protection drugs and health products. Novartis Beijing was founded by Novartis AG and Beijing Pharmaceutical group and Beijing Zizhu Pharmaceuticals in 1987, the first foreign pharmaceutical company in China.
• Sanofi-Aventis The German-French company sells several drugs in China. Sanofi Aventis runs three facilities in Beijing, Shenzhen and Hangzhou; currently, they're in the process of building a brand new Vaccine Plant outside Shenzhen.
• AstraZeneca Pharmaceutical Co. has its headquarters in Shanghai, with 25 branch offices in major cities across China's mainland. In 2001, the company established its largest manufacturing site in Asia with a total investment of $170 million in Vuxi. It sells several products, including Seroquel va Nexium. It has nearly 3,000 employees working in manufacturing, sales, clinical research and new product development. It has a presence in more than 110 targeted cities, with around 800 representatives.^[24] Arxivlandi 2007 yil 19 dekabrda Orqaga qaytish mashinasi
• Bristol-Mayers Squibb is one of the earliest to enter Chinese market.
• Jonson va Jonson sells Tynoline and other drugs in China.
• Vayt 's best-seller in China includes Calcium-D.
• Roche launched a medical education campaign targeting 3,500 doctors in 20 Chinese cities in 2004.
• Schering-Plow is a worldwide pharmaceutical company committed to discovering, developing and marketing of new medicines that can improve people's health and extend life. The company is the recognized leader in biotechnology, genomics and gene therapy. Shanghai Schering-Plough Pharmaceutical Co., Ltd, with a total investment of US 37 million, was founded on August 5, 1994 as a joint-venture, with Shanghai Pharmaceutical Industry (Group) Corporation and Shanghai Corporation of Pharmaceutical Economic and Technical International Cooperation.
• Bayer Greater China is Bayer 's second largest single market in Asia, accounting for approximately one quarter of regional sales. Its interests in this region have grown steadily over the years, from step-by-step investment in the early 1990s to large-scale, world-class facilities today. Bayer's investment in our integrated production site in the Shanghai Chemical Industry Park makes it evident that Bayer regards Greater China as one of its most important markets worldwide. Bayer's Greater China Group operates in the market encompassing Hong Kong, Taiwan, and China. The Bayer Group in Greater China is led by management holding companies, with the subgroups and production joint ventures operating independently under their strategic direction. The Country Group Speaker, Dr. Elmar Stachels, leads the Group in Greater China. The Greater China Group employs ca. 2,800 people across a wide range of functions. Companies and Locations: Bayer currently operates 18 companies in Greater China. Eight of them now have production facilities on stream in all business segments in which the company is active. Local production accounts for an increasing proportion of sales. Bayer China is engaged in a number of cooperation projects with some of the foremost research institutes and universities in China, to conduct research in the field of innovative materials, health care and crop science. It strongly cooperates with the Chinese Academy of Science and affiliated institutes such as the Institute of Materia Medica and the Kunming Botanika instituti yilda Yunnan with the aim to identify new compounds in the healthcare and crop science field. There are also a number of projects currently being started in polymers research. In addition, Bayer also supports a number of chairs and programmes for research and teaching at Chinese universities. These include the Tsinghua-Bayer Public Health and HIV/AIDS Media Studies Program, a national platform designed to play a key role in China's public health system. Furthermore, Bayer HealthCare supports a chair for Healthcare Management at the China European International Business School (CEIBS) in Shanghai.
• Boehringer Ingelheim entered Chinese market in 1995 and invested $25 million in a new facility in Shanghai in 2002. Its drugs treating respiratory diseases and cardiovascular diseases have established well in Chinese pharmaceutical markets.
• Hoechst Marion Russel established its China head offices in Beijing in 1995 to manage operations in mainland China and Hong Kong. HMR has two joint ventures in China, Hoechst Huabei Pharmaceuticals Ltd in Shijiazhuang, a heartland of the Chinese pharmaceutical industry, and Hoechst Shanghai International Pharmaceuticals Ltd.
• Eli Lilly set up its first overseas office in Shanghai in 1918 and returned to Shanghai, China in 1993. Its main facility is in Suzhou, Jiangsu province and main products include Ceclor, insulin, and erectile dysfunction drug ED.
• Abbott Laboratories Ltd sells a series of products including baby food in China.
• Xian-Janssen: Among foreign-invested ventures in China, Xian-Janssen Pharmaceutical, joylashgan Sian is regarded as a model. It has ranked among the top 10 joint ventures in terms of revenue since 1991, thrice landing in the number one spot. The company's success is due partly to its product line, which includes a range of high-volume sellers: medicines to treat gastronintestinal problems, fungi, allergies and pain, as well as psychosis and epilepsy. But it was Dr. Pol Yanssen 's decision to enter China early, to invest inland, and to keep investment plans moving along in the wake of 1989 Tiananmen Square event that have helped build its good relations with the Chinese government. Paul Appermont va Joos Horsten lead the Xian-Janssen Pharmaceutical project.
• Degussa is shifting a large proportion of its pharmaceutical chemicals production from Europe to China in order to take advantage of low-cost manufacturing and improved production efficiencies in the country. At the same time, the company will restructure some of its large production facilities, the vast majority of them in Germany, which could result in the transfer of the manufacture of other products to China.
• Rodiya is improving its competitive position in analgesics by reinforcing its more cost-effective manufacturing operations. The company is making a major investment in its Wuxi, China, paracetamol (acetaminophen or APAP) production facility and consolidating its North American and European operations. Rhodia shuttered its Luling, La., paracetamol operations in 2004 and consolidated production in Roussillon, France, and Wuxi, China. Following these changes, paracetamol production capacity will be adjusted to match current levels.

Japanese companies:

• Sankyo: Having previously generated revenues from exports to local agencies allied with its own marketing, Sankyo completed a plant for manufacturing its drugs in October 2003, and plans to expand its own marketing. It expects to double the number of marketing representatives (MRs) to 130 in 2004, and increase sales in China from ¥3.0 billion currently (company estimate for 2003) to ¥5.0 billion within a few years. Sankyo already markets hyperlipemic Mevalotin, anti-inflammatory Loxonin, and antibiotic Banan in China, and plans to market hypertensive Olmesartan (currently under development) there in future.
• Takeda: The company basically does its own marketing (sales value estimated to be ¥1-2 billion). It also has a manufacturing plant. In 2004 Takeda planned to launch diabetes drug Actos in China, and then it will be marketing all four global products (Actos, anti-ulcer Takepron, cancer drug Leuplin, and hypertensive Blopress). However, the US has priority in its overseas strategy, followed by Europe and then Asia.
• Yamanouchi: The firm moved into China in 1994 and does most of its own marketing, covering anti-ulcer Gaster and urinary impediment treatment Harnal among its leading products. Sales are gradually expanding, and operating profitability was achieved in 2001. Accumulated losses have been wiped out during F2003. The company owns a manufacturing plant. In 2004, there are plans to launch Dolner for peripheral circulation, anti-emetic Nazea OD, and hypertensive Hypoca. Yamanouchi does not have plans to increase its 110 MRs significantly at this point.
• Daiichi: Shifted to in-house marketing after establishing a sales subsidiary in 1998, mainly selling synthetic antibacterials Cravit (oral and injectable) and Tarivid. It originally planned to launch neurotransmission enhancer Translon too, but after development was halted in Japan, development in China also ended. In 1998, it forecast sales of ¥12.0 billion in 2002, but only actually recorded ¥1.6 billion. Sales are behind plan chiefly due to the suspension of Translon's development and the proliferation of generic and copycat versions of Cravit. On the earnings side, Daiichi expects to move into operating profit in F2004 as Cravit sales expand. It does not currently plan to expand its force of MRs much from 140–150, but expects to do so when urinary impediment treatment KMD-3213 (Phase 1 under preparation) is launched, which will be 2007 at the earliest.
• Tanabe: Markets in-house products such as hypertensive Herbesser and Tanatril. Tanabe does not disclose mediumterm targets, but plans to double the number of MRs to 200 by the end of 2005. No products are currently in clinical trials, but there are a number of development candidates.
• Mitsubishi Tanabe Pharma: The China subsidiary Kuangchou Green Cross has been extending transfusion business (manufacturing, sales) since the days of the former Yashil xoch, but both sales and profits have been flat for the past several years. The firm has already sold off its transfusion business in Japan to Otsuka Pharmaceutical as part of its restructuring, and the strategic importance of this is diminishing. Anti-coagulant Novastan, which was approved and launched in China in December 2002, is being sold not via Kuangchou Green Cross but by a local agent.
• Astellas: Immunosuppressant Prograf is being marketed in China by an 80%-owned subsidiary An application has been filed to sell a second product, atopic dermatitis treatment Protopic. It has a relatively large number of MRs at 30-40 (the subsidiary has 60 employees); by comparison, Prograf has 40 MRs in the US. China business is less of a priority for Astellas than the US or Europe, but sees its potential as significant due to the large number of organ transplants. In 2000, there were 5,501 kidney transplants performed in China, second only to the number in the US (13,372). Sales of immunosuppressant drugs are relatively high. The top 30 drugs by sales in China (hospital market base) included two such drugs: Novartis' Neoral at number 22 ($16.1 million), and Roche's CellCept at 23 ($15.8 million).
• Chugay: China is not positioned as a priority market for Chugai, which has focused on Europe since coming under the Roche group. Exports of white blood cell production stimulant Neutrogin account for most of its business in China, with marketing consigned to agents. Kirin's Gran, another GCSF drug, is marketed in China by Kirin itself and recorded 2002 sales of $11.1 million, ranking it 45th in the hospital market.
• Eisai: The firm expanded its own manufacturing and marketing operations into China and Asia earlier than in the European and US markets. Its sales and profits in F2002 and own projections for F2003 place Eisai as number one among Japanese firms in China. Eisai was the first manufacturer among the US, European and Japanese pharmaceutical firms to manufacture in China via a 100% owned subsidiary from the very beginning (founded in 1994). The sales target for 2006 is an ambitious ¥20 billion. By 2006, Eisai plans to increase the number of MRs from 150 to 250, and extend its coverage from 1,000 hospitals in 53 cities to 3,000 hospitals in 100 cities. It already sells two global products, anti-ulcer drug Pariet and Alzheimer's treatment Aricept, and plans to add osteoporosis drug Glakay in 2006.
• Kyowa Hakko: Having previously only exported cancer drugs (a few hundred million yen's worth), Kyowa Hakko plans to get approval and then start marketing itself thehypertensive Coniel at the end of 2004. Ant-allergy Allelock should also go on sale in 2007, with peak sales for the two combined projected by the firm at over ¥2 billion.
• Taisho: The company makes and sells health drinks (tonics) in China, but has no specific plans for prescription drugs. The rights to antibiotic Clarith/Biaxin outside Japan are licensed to Abbott.
• Terumo: Unlike the drug makers, Terumo is using China as a manufacturing base (almost all of its 1,362 employees there are in manufacturing). Its manufacturing subsidiary when set up in 1995 specialized in making products for the Japanese market, but more recently this has been producing and shipping products for the US and Europe as well. Terumo is still in the process of exploring China as a market, however. For more than 20 years, it has sold products using agents in China via its Hong Kong subsidiary, but F2002 sales amounted to only ¥1.3 billion (low-margin products are not handled, so there are profits). It plans to consider the possibility of in-house marketing, going forward.

Foreign companies doing R&D in China

Xitoy kirib kelganidan keyin JST, many leading pharmaceutical companies are transferring their research and development centers to China. Masalan; misol uchun, Roche of Switzerland opened its R&D center in Shanghai recently, GSK has established its OTC research and development center in Tyantszin, Xitoy va Pfizer va Janssen Pharmaceuticalica (Jonson va Jonson ) will carry out similar plans in the near future. AstraZeneca, Bayer, Eli Lilly va Kompaniya va Xofman-La-Rosh, have also set up R&D or klinik sinov centers in China.

A poll on 33 foreign pharmaceutical enterprises in China shows that seven out of the 33 companies have R&D centers in China, accounting for 22% of the surveyed. The remaining 26 pharmaceutical enterprises have no R&D centers in China, accounting for 78% of the surveyed. All the R&D centers were founded after 1999, mainly in 2000 and 2001.

In January 2004, Roche of Switzerland opened its research and development center, the fifth R&D center of the pharmaceutical giant, and the first to be established in China. Roche planned to hire 40 to 50 scientists in the first year and focus their research on farmatsevtik kimyo o'rganish. The center aims to step into an'anaviy xitoy tibbiyoti tadqiqot.

• Novo Nordisk has a $10 million research-and-development center at the Shangdi High-Technology Park in Beijing.
• Lonza (Basel, Switzerland, www.lonza.com) has opened a facility in Guangzhou, China;
• Discovery Partners International (San Diego, CA, www.dpi, com) has affiliates in China.
• Chiral Quest has a research and development facility at a biotechnology R&D park at Jiashan, China near Shanghai.
• Affimetriya, Inc. va CapitalBio Corporation, a leading life science company based in Beijing, China formed a strategic relationship to jointly develop and co-market a proprietary, advanced GeneChip.

Foreign companies doing drug testing or clinical trials in China:

• SiniWest Holdings; Headquarters: San Diego; Product Tested in China: Drugs to treat breast cancer and peptic ulcers; Current Status: Did preliminary studies in China; plans U.S. research trial.
• Cancer Therapeutics; Headquarters: Los Angeles; Product Tested in China: Treatment involving antibodies that deliver radiation to kill cancer cells; Current Status: Expects approval in China this summer; approval in U.S. still three to four years away.
• FeRx; Headquarters: San Diego; Product Tested in China: Drug to treat liver cancer; Current Status: In research trials in both U.S. and China.
• Frontage Laboratories; Headquarters: Pennsylvania; Products Tested in China: Helping domestic firms to conduct IND enabling studies for new CNS, Cancer and Cardiovascular drugs with GLP operations in Shanghai, GMP operations in Beijing, and Clinical operations in Beijing and Zhengzhou (currently established 150 research beds in two centers); Current Status: In drug development experiments, preclinical and clinical trials in both US and China.

Hukumat siyosati

China's pharmaceutical industry has been a major industry that was completely directed by the state and subject to markaziy rejalashtirish, upon which transition-era reforms since the 1980s to this day have had a major impact. The pharmaceutical industry has been shaken up following the implementation of several government-initiated structural reforms.^[25]

The main reforms included:

1. Requiring all pharmaceutical manufacturers to meet GMP standards by 2004,

2. Diminishing drug sales through hospitals,

3. Bidding publicly for drug purchase,

4. Implementing a national healthcare insurance system, and

5. Strengthening intellectual property protection and SFDA supervision.

The overall goal has been to improve manufacturing and distribution efficiencies, strengthen drug safety supervision, and separate hospitals from the drug retailing business.

Tartibga solish

With the increasing growth of the Chinese pharmaceutical market, the government realised the importance of supervision of pharmaceutical market. They put forward several regulations and reform measures over the past couple of years, especially in the recent period of healthcare reform. The most influential issues for foreign companies are the decree of Administration Method of Import Pharmaceuticals recently promulgated by the State Drug Administration, and the launch of a new version of registration certificate for import pharmaceuticals. Despite these advances China is still the leading manufacturer of counterfeit drugs, which claim the lives of people worldwide every year. In June 2009, Nigeria seized a large consignment of fake anti-malarial drugs with the label of 'made in India' but found that the medicines were in fact produced in China and were imported into the African countries.[4] The authorities maintained that the incident was not isolated, indicating that more fakes were circulating.

Regulatory agencies

• Davlat oziq-ovqat va farmatsevtika idorasi: As part of the government restructuring announced in March 1998, the Ministry of Health's Department of Drug Administration merged with the State Pharmaceutical Administration of China (SPAC) to become the State Drug Administration (SDA). As a result, SDA oversees all drug manufacturing, trade, and registration. In 2003, the SDA was restructured to become the State Food and Drug Administration.

Other former functions of the ministry have been assigned to different government bodies. The most important of these was the transfer of medical insurance responsibilities to the new Ministry of Labor and Social Security. Nonetheless, the Ministry of Health retains its other main functions-regulatory development and oversight, healthcare resource allocation, and medical research and education. The Chinese government's establishment of a single drug regulatory authority was an important step toward foreign access, because it eliminated the conflicting standards that prevailed among provincial government agencies, centralized the Chinese healthcare regulatory system, and made it more transparent. SFDA now oversees all medications-both Western and TCM-as well as advertising. Its new regulations follow FDA's model. Depending on the product and circumstance companies seeking to receive pharmaceutical approval might additionally have to register their product with the General Administration of Quality Supervision, Inspection and Quarantine AQSIQ.In July 1999, as part of medical insurance reform, SFDA released its first list of over-the-counter (OTC) medications, and in 2000, the state began to regulate OTC and prescription drugs separately. SFDA did so to encourage patients to purchase OTC medicines for less serious diseases, thereby reducing government medication expenditures and hospital visits. The SFDA plans to cut the number of manufacturers down to around 2,000 over the next two years by attrition and by requiring remaining firms to meet the new GMP standards. In fact, SFDA required all pharmaceutical companies in China to obtain GMP certificates from SFDA by June 30, 2004 to be licensed to sell their drug products in China. About 3000 of the companies met the deadline; companies in the process of obtaining certification may subcontract secondary production to a certified company until June 30, 2005.

In 2005, SFDA launched a regulation on drug research and supervision management aimed at enforcing GLP to investigative drugs, traditional Chinese medicine injections and biotechnology products. The regulation aims to help China's drug research and development gain international recognition.

• Milliy taraqqiyot va islohotlar komissiyasi: The function of the agency includes making strategic planning and mid to long term planning for the Chinese pharmaceutical industry, regulating the prices of drugs, managing disaster relief funds and carrying out the pharmaceutical development projects sponsored by the government.
• Ministry of Commerce: The government organization regulates the import and export of medical devices and equipment, collects and analyzes import and export data, and carries out anti-dumping investigations.
• Ministry of Labor and Social Security: The agency is responsible for the management of state medical insurance systems.
• Ministry of Health: The agency guides the reform of the medical service industry, is responsible for clinical trials and clinical applications of drugs, joins with other agencies in monitoring the severe side effects of drugs, and makes the basic insurance drug list.
• State Traditional Chinese Medicine Administration: The agency focuses on policies and regulations related to traditional Chinese MEDICINES.
• State Population and Family Planning Commission: The agency writes the regulations on the use of birth control tools and pills.
• Ministry of Science and Technology: The agency determines new product development projects, evaluates and registers new research and development achievements; issues grants and funds for small to mid business innovative investment.
• State Quality Control Administration: It enacts and implements national standards.
• Industrial Associations: Include China OTC Association, China Pharmaceutical Quality Management Association, China Pharmaceutical Commerce Association, and others.

Normativ talablar

China quickly advanced its pharmaceutical-related regulations around the time of its December 2001 entry into the World Trade Organization (WTO). China has strengthened Patent protection: In conformity with the WTO/TRIPS agreement, the patent protection structure adopted by China approaches that of Japan, Europe, and the US. Since the end of the 1990s, the government has been striving to develop a healthcare insurance system that covers 200 million Chinese. Already, 90% of the population in major cities like Shanghai, Beijing, and Guangzhou are covered, for a total of over 80 million. The Pharmaceutical Management Law was overhauled in December 2001, and various regulations were enacted from 2002–2003. Transparency in the approval process is gradually improving.

Following WTO regulations, China has committed itself to cutting tariflar, liberalizing its domestic distribution practices, and restructuring its regulatory environment. China has allowed foreign enterprises to import products and engage in distribution services. Furthermore, China has also implemented new drug administration laws designed to tartibga solish product registration and protect Intellektual mulk huquqlari (IPR). China has agreed to six years of "data exclusivity" and has committed itself to implementing a patent linkage system. The SFDA has worked to crack down on qalbaki shaxslar but without greater resources and stricter legal consequences, these actions alone have yet to be enough to curb this rampant problem.

Since 1998, the government has raised the bar for entering the pharmaceutical business by passing laws including Drug Management Law and Regulations on Pharmaceutical Manufacturing. They involve following aspects of pharmaceutical manufacturing, drug distribution and selling, drug registration, requirements for manufacturing traditional Chinese medicines, medical packaging manufacturing requirements, and medical device manufacturing requirement.

The new laws will likely have an adverse effect on market growth and profitability during the transitional period, but over the next 5–10 years this market should be able to provide the returns.

Government drug pricing policy

In order to alleviate the burden of medical expenses on the society and ensure the implementation of the medical insurance scheme, retail prices of pharmaceutical products qualified for the program and included in the National Basic Medical Insurance Scheme Drug Catalogue will be regulated. The pricing mechanism is based upon three considerations when setting the maximum retail price - production cost, a wholesaler spread set by the government and the prices of comparable products in the market. Any products priced above this level will be cut.

Centralized tendering drug procurement program

The centralized tendering procurement system operates in two ways. First, several hospitals and medical institutions join together to invite tenders. Then, they appoint qualified agents to handle tenders. These agents are prohibited from having ties with the industry regulatory or administrative bodies.

In 2002, 70% of public hospitals at county or above level implemented this tendering system. This system has successfully passed the pilot phase and proven effective. Both the number of participating hospitals and variety of drugs expanded substantially.

More power to hospitals and medical institutions. In a market economy, hospitals and medical institutions do their own drug procurement. They source drugs from manufacturers at market prices and dispense them to patients. The centralized tendering drug procurement system, however, gives more power to hospitals in drug procurement. As a result, some unfair, unjustified and unreasonable practices surface as decision makers of some hospitals abused their power in order to get economic benefits.

GMP compliance certification

GMP is a system to ensure products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. A directive circular issued by the Ministry of Health in Jul 95 marked the official launch of GMP certification in China. The China Certification Committee for Drugs (CCCD) was established in the same year. A subsidiary organization was also set up to manage the certification program.

Currently nine government agencies are the key agencies responsible for regulation. They are the State Food and Pharmaceutical Administration (SFDA), the State Development and Reform Committee, the Commerce Ministry, the State Traditional Chinese Medicine Administration, the Ministry of Labor and Social Security, the Ministry of Health, the State Population and Family Planning Committee, the Ministry of Science and Technology, and the State Quality and Technology Supervision Administration.

In addition, more than 10 industrial associations also regulate the industry.

Comparison of regulatory requirements with other countries

The enforcement of Good Manufacturing Practices has not been adequate in China and the U.S. FDA and EMA (European Medicines Agency) have inspected Chinese pharmaceutical plants that export to their countries and found many to be seriously non compliant with GMP.^[26][27]

There is only federal regulation on new drug application, but there are both local regulation and national regulation regarding pharma expenditures of hospitals, reimbursable drug lists, and other issues. National regulation is implemented by SFDA and other state agencies, while local regulation is implemented by provincial agencies.

Through related laws, China has established a physician licensing system, which requires physicians to pass a national exam to be eligible for applying for licenses. After passing the exam, physicians will be eligible for applying for certificates for the practice of medicine. Licensed physicians can open their own clinics five years after getting licenses, during which they must work as physicians.

There is a mechanism for approving new drugs (from NDA filing to approval). A full three-phase research trial takes three to five years, similar to the U.S., while requirements to start a trial are onerous by foreign standards, according to Western drug-company executives.

Although the approval time is being shortened, there still remain many aspects where transparency is lacking.

Patentlar

Western pharmaceutical companies have applied for numerous patentlar Xitoyda. About 10,000 patents for traditional Chinese medicines belong to Western companies. However, some Western observers say China lacks administrative protection for patents.

In 1992, the United States and China signed a memorandum of understanding (MOU) to allow administrative protection (AP) in China for US pharmaceutical patents granted between 1986 and 1992. The MOU provided seven-and-a-half years of market exclusivity, or AP rights, in China for pharma patents that were: not protected by exclusive rights before the amendment of current Chinese laws; patent protected after 1 January 1986 and before 1 January 1993 in an MOU signatory country; not previously marketed in China. Several Chinese government policies have prevented US industry from realizing the intended MOU benefits. According to Article 42 of the Patent Law, the duration of patent right for inventions is twenty years, and the duration for utility models and patent right for designs is ten years, counted from the date of filing.

The Intellektual mulk davlat idorasi is responsible for enforcing patents. The intellectual property system in China was originated from and developed as a result of the policy of reform and opening-up. The State Council, the Patent Office of China, the predecessor of SIPO, was founded in 1980 to protect intellectual property, encourage invention and creation, help popularize inventions and their exploitation, and promote the progress and innovation in science and technology.

In 1998, with the restructuring of the government agencies, the Patent Office of China was renamed SIPO and became a government institution under the direct under control of the State Council. The office is in charge of patent affairs and deals with foreign-related intellectual property issues.

Amerika Qo'shma Shtatlari va Xitoy

A'zosi sifatida Jahon intellektual mulk tashkiloti, China is active in protecting international patents. The SIPO has signed intellectual property protection memorandums with countries including Russia and Thailand on the protection of intellectual properties. Such agreements are necessary to protect international patents in China.

On July 14, 2005, China and the United States reached an agreement on intellectual property protection. According to western pharmaceutical business journals, most discouraging to US pharmaceutical companies has been the rampant theft of their intellectual property through patent infringement and counterfeiting. All those factors undermined the competitive advantage that innovative pharmaceutical companies stood to gain from marketing investments. As a result, US companies accounted for less than 10 percent of China's total pharmaceutical imports between 1998 and 2000.

Xitoy yaqinda Urugvay raundining savdo bilan bog'liq intellektual mulk to'g'risidagi bitimini amalga oshirishga kelishib oldi. Bunga rioya qilish uchun Xitoy kompaniyalari soxta mahsulotlarga ishonish bo'yicha uzoq yillik amaliyotini o'zgartirishi kerak. Xitoyning Securities Times gazetasiga ko'ra, chet el kompaniyalari patentlangan dori-darmonlarni nusxa ko'chirgan kompaniyalarga nisbatan 400 million dollardan 1 milliard dollargacha bo'lgan tovon puli to'lashlari mumkin.

18 va 19-moddalar

Xitoyning patent qonuni chet el kompaniyalariga 18 va 19-moddalarda murojaat qiladi. 18-moddaga binoan, har qanday chet el fuqarosi, chet el korxonasi yoki Xitoyda odatiy yashash joyi yoki ishbilarmonlik vakolatxonasi bo'lmagan boshqa xorijiy tashkilot Xitoyda patent olish uchun ariza topshirsa, talabnoma tegishli tartibda ko'rib chiqiladi. tashkilotni qabul qiluvchi davlat va Xitoy o'rtasida har qanday kelishuv bilan yoki har ikki davlat ishtirok etgan har qanday xalqaro shartnomada yoki o'zaro kelishuv printsipi asosida.

19-moddaga binoan, agar bunday tashkilot patent olishga murojaat qilsa yoki boshqa patent masalalari Xitoyda bo'lsa, u o'zining vakili sifatida ishlash uchun Davlat Kengashi huzuridagi patent ma'muriyati bo'limi tomonidan tayinlangan patent agentligini tayinlashi kerak.

Patent agentligiga qonunlar va ma'muriy qoidalarga rioya qilish, patent talabnomalari va boshqa patent masalalarini o'z mijozlarining ko'rsatmalariga binoan ko'rib chiqish majburiyati yuklangan. Agentlik mijozlarning ixtirolari tarkibidagi maxfiy ma'lumotlarni saqlashga mas'uldir. Patent agentligini boshqaradigan ma'muriy qoidalar Davlat kengashi tomonidan ishlab chiqilgan.^[28]

Tarqatish

Xitoy farmatsevtika tarqatish sektori taxminan 10,000 dan ortiq davlat farmatsevtika ulgurji savdogarlari bilan juda parchalangan. Rivojlangan mamlakatlarda reklama bilan to'ldiriladigan asosiy marketing faoliyati bo'lgan shifokorlarga to'g'ridan-to'g'ri marketing (tafsilotlar) Xitoyda rivojlanmagan. Xitoy shifoxonalari sotishdan tushadigan daromadlarining 60 foizini tashkil qiladi retsept bo'yicha dorilar. Kasalxonalardagi dorixonalar hanuzgacha farmatsevtika vositalarining asosiy chakana savdo nuqtalari bo'lib, ular umumiy dori sotilishining 80 foizini tashkil etadi. Bu holat o'zgarib bormoqda, chunki hukumat kasalxonalar bilan bog'liq bo'lmagan chakana dorixonalarni tashkil etishni rag'batlantiradi.

Giyohvand moddalar Xitoyda xitoycha uslubdagi kanallar orqali tarqatiladi. Xitoyda uch bosqichli tarqatish tizimi mavjud. Narvonning yuqori qismida milliy 1-daraja stantsiyalar Pekin, Shanxay, Shenyang, Guanchjou va Tyantszin. Ular mahsulotlarni viloyatga ajratadilar daraja-2 o'z navbatida tuman va shaharga sotadigan distribyutorlar 3-daraja ulgurji-dori do'konlari. Tarqatish zanjirining pastki qismida Xitoyning juda ko'p sonli kichik chakana do'konlari joylashgan bo'lib, ularga alohida etib borish qiyin.

Farmatsevtik logistika

Ayni paytda Xitoy farmatsevtika logistikasi sanoat kichik miqyosli, tarqoq sarmoyalar va shiddatli xususiyatlarga ega musobaqa. Xitoyning farmatsevtika logistika sanoati asosan farmatsevtika ishlab chiqaruvchilari va farmatsevtika distribyutorlaridan iborat. Xitoyda 16,500 ulgurji savdogar, 120 ming chakana savdo va 6300 dan ortiq ishlab chiqaruvchilar mavjud. Sotish hajmi bo'yicha Xitoyning eng yaxshi uchta kompaniyasi: Sinofarm guruhi, Shanxay farmatsevtika kompaniyasi va Jiuzhoutong Group Corp., barchasi milliy bozorning 5 foizidan kamrog'iga ulangan.

2002 yildan beri Xitoyning farmatsevtika logistika sanoati doimiy ravishda kengayib bormoqda. Sanoatga katta miqdordagi kapital quyilmoqda. 2007 yilda Xitoyda uchta farmatsevtika logistika markazi ishga tushirildi, ya'ni Jiangsu Yabang tibbiyot logistika markazi, Quanzhou tibbiyoti va oziq-ovqat logistika porti va Chongqing Medicine Heping Logistika Markazi.

2007 yilda qurilishni boshlagan yirik farmatsevtika logistika loyihalariga Xitoy-ASEAN (Tongji) tibbiyot logistika markazi, Guangxi Tongji Medicine Group tomonidan 145 million CNY, Nantong Suzhong farmatsevtika logistika markazining umumiy sarmoyasi bilan 280 million CNY va Chongqing zamonaviy tibbiyoti kiradi. Logistika markazi loyihasi Shenzhen Neptunus Bioengineering Co., Jinguan Group va Chongqing Huabo Medicine Co.

Dan olingan statistik ma'lumotlarga asoslanib Xitoy farmatsevtika tijorat assotsiatsiyasi va Xitoyning tibbiyot va sog'liqni saqlash mahsulotlarini import va eksport qilish assotsiatsiyasi, Xitoyning farmatsevtika logistika sanoatining xususiyatlarini inobatga olgan holda, Xitoy shoshilinch ravishda sanoatni qayta qurish va ittifoq tuzish orqali yirik transmintaqa, trans-sanoat va trans-mulkchilik guruhi bo'lgan farmatsevtika logistika konglomeratlar guruhini yaratishni talab qilmoqda. Logistika markazlari qurilishiga kelsak, ularni birgalikda qurish yaxshiroqdir. Shu tarzda, bu dori-darmon oqimini tezlashtirish, aylanish samaradorligini oshirish va logistika narxini pasaytirish uchun butun logistika operatsiyalari bo'yicha boshqaruvni amalga oshirishga yordam beradi.

Oxirgi foydalanuvchilar

Xitoyda oxirgi foydalanuvchilarning ikki turi mavjud: kasalxonalar va chakana savdo farmatsevtika franchayzing do'konlar. 2004 yilda 16 ta shahardagi shifoxonalarda o'tkazilgan namunali tekshiruv natijalariga ko'ra, Xitoy shifoxonalari 2003 yilga nisbatan 27 foizga ko'paygan holda umumiy 2,5 milliard AQSh dollarlik dori-darmon sotib olgan deb taxmin qilingan. 2004 yilda farmatsevtika franchayzing do'konlarining umumiy daromadi 5,6 milliard AQSh dollarini tashkil etdi. , 2003 yilga nisbatan 36% ga o'sdi.

Chakana savdo operatsiyalari

Xitoyning ilgari rejalangan iqtisodiyot tizimi tufayli kasalxonalar hanuzgacha farmatsevtika mahsulotlarining asosiy distribyutorlari bo'lib qolmoqda. 2003 yilda giyohvand moddalarga sarflangan xarajatlarning atigi 15,1% sarflangan dorixona do'konlar. (Meng 2005) Xitoy hukumati 2003 yilda chakana dorixonalarga xorijiy mulk huquqini rasmiylashtirdi. Korporatsiyalar Alliance Boots asosan Xitoyda chakana savdo va tarqatish bo'yicha qo'shma korxonalar tuzdilar Guandun viloyat.^[29]

Ko'pgina kompaniyalar Xitoyda giyohvand moddalarni tarqatish tizimi samarasiz ekanligini va dori-darmonlarning chakana narxlariga sezilarli darajada qo'shilishini ta'kidladilar. Shuningdek, noaniq me'yoriy hujjatlar, past rentabellik, litsenziyalashning murakkab tartibi, shifoxona savdosi va xarajatlarni qoplash sxemalari bo'yicha shikoyatlar kelib tushdi.

Xun takviyeleri

The xun takviyeleri sub-sektor 1998 yilda 3 milliard dollardan ikki baravar ko'payib, 2001 yilda umumiy savdo hajmi 6 milliard dollarni tashkil etdi. Mutaxassislarning taxminlariga ko'ra, sanoat 2010 yilga borib yillik savdo hajmini 10 milliard dollarga etkazadi va iste'molchilar sog'lig'ini sog'aytiradigan va boshqa sog'liqqa ega mahsulotlarni qidirishda davom etadi. kuchaytiruvchi effektlar. Oziq-ovqat qo'shimchalarining 3000 dan ortiq mahalliy ishlab chiqaruvchilari 4000 dan ortiq turdagi mahsulotlarni ishlab chiqaradilar. Mahalliy ishlab chiqaruvchilar tovar belgilari va ishonchliligini rivojlantira olmaydilar va savdo-sotiqni yaratish uchun reklamaga katta ishonadilar. Shunday qilib, aksariyat mahalliy mahsulotlar, iste'molchilar orasida ishonchni yo'qotishi sababli, qisqa muddatga ega hayot davrlari. Import qilingan yuqori sifatli mahsulotlar umumiy savdo hajmining atigi 10 foizini tashkil qiladi. Kompaniyalarning ta'kidlashicha, mahsulotni murakkab ro'yxatdan o'tkazish, qimmat va ko'p vaqt talab qiladigan sertifikatlash talablari, tajribasiz va samarasiz distribyutorlar odatdagi to'siqlardir.

Ta'lim va tadqiqot

Xitoyda shug'ullanadigan ko'plab oliy o'quv yurtlari mavjud farmatsevtika tadqiqotlari. (Qarang Xitoyda farmatsevtika oliy o'quv yurtlari.)

Intellektual mulk huquqlari

Shuningdek qarang

• Xitoy farmatsevtika sanoat assotsiatsiyasi
• Xitoyda dorixona
• Xitoyda tibbiyot va Xitoyda sog'liqni saqlash
• Farmatsevtika siyosati
• Milliy farmatsevtika siyosati
• Farmatsevtika marketingi
• Farmatsevtika kompaniyalari ro'yxati
• Oqsillar tarkibini bashorat qilish
• Dori vositalarining dizayni
• Ratsional dori dizayni
• Bioinformatika
• Kimyoviy informatika
• Biomedikal informatika
• Yetim dori
• Fiziologik asoslangan farmakokinetik modellashtirish
• Hindistondagi farmatsevtika
• Umumiy dori
• Yangi kimyoviy birlik (NCE)
• Sifatni tekshirish (QA)
• Sifat nazorati (QC)
• Farmakologik nazorat
• Davlat oziq-ovqat va farmatsevtika idorasi
• Sifatni nazorat qilish, tekshirish va karantin bo'yicha umumiy ma'muriyat

Izohlar va ma'lumotnomalar

Bibliografiya

• Men, Cheng, Kumush, Quyosh, Rehnberg, Tomson. (2005) "Xitoyning dori vositalarining chakana narxlarini nazorat qilish siyosatining shifoxona xarajatlariga ta'siri: Shandun kasalxonasining ikkita kasalxonasida amaliy ish". Oksford universiteti matbuoti. [1]
• Xu Yuanjia, Karolina O.L. Ung, Byan Ying va Van Yitao. "Xitoy farmatsevtika bozori: dinamikasi va taklif qilingan investitsiya strategiyasi". Tibbiy marketing jurnali (2007) 7, 18–24. doi:10.1057 / palgrave.jmm.5050061 [2]
• Eliza Yibing Chjou. Xitoy farmatsiyasi o'z diqqat markazida 2007 yil 1-mart (Klinik tadqiqotlar va diagnostika Kanal jildi 27, № 5)
• Cheri Greys. Xitoy farmatsevtika sanoatida intellektual mulk huquqlarini o'zgartirish 2004 yil iyun (Dori vositalariga kirish) DFID sog'liqni saqlash tizimlari resurs markazi
• Xitoy farmatsevtika sanoati ishlab chiqarish o'rtacha 20 foizga o'sdi - Reuters 2008 yil 9-yanvar
• Farmatsevtika sanoatining kengayishini ta'minlash uchun patent tizimi - Xitoy qonuni va amaliyoti, 2008 yil may
• 2007-2008 yillarda Xitoy farmatsevtika sanoatini rivojlantirish bo'yicha yillik hisobot^{[o'lik havola ]} Sanoat tadqiqot markazi, CCID konsalting
• Jan-Fransua Trembley Xitoyning farmatsiyasi kashfiyotga sakraydi Kimyoviy va muhandislik yangiliklari 2008 yil 4 fevral, 86-jild, 05-son 11-15 betlar.
• Api ishlab chiqaruvchisi Api etkazib beruvchisi va api ishlab chiqaruvchisi Api etkazib beruvchisi va api ishlab chiqaruvchisi
• Seamus Grimes va Marcela Miozzo (2015) Big Pharma tomonidan Xitoyga ilmiy-tadqiqot ishlarini xalqarolashtirish, Evropani rejalashtirish tadqiqotlari. 23 (9) 1873-1894.

Tashqi havolalar

• Xitoyda farmatsevtika sanoati uchun moliyaviy inqiroz haqida nima deyish mumkin?, Asia Manufacturing Pharma
• Xitoyning API sanoatida moliyaviy inqiroz bilvosita ta'sir qilishi kutilmoqda, Asia Manufacturing Pharma
• ChinaBio tezlatgichi Arxivlandi 2007 yil 8-dekabr kuni Orqaga qaytish mashinasi, notijorat tashkilot
• Xitoyning giyohvand moddalar sanoati rivojlana boshladi, 11 oktyabr 2007 yil Kimyo olami, RSC
• Xitoy dori-darmonlarini rivojlantirishga qaratilgan ulkan loyiha, 2008 yil 15-yanvar, kimyo olami, RSC
• Xitoyning biofarmatsevtika sanoati sanoati rivojlangan mamlakatlar bilan tenglasha oladimi? (2006 yil 9-may) Rivojlanish uchun Fan va Texnologiyalar Milliy tadqiqot markazi
• Xitoy global farmatsevtika roli tomon qadam tashlamoqda 2007 yil 12 mart Kimyo va muhandislik 85-jild, 11-son 15-19 betlar
• Xitoyning farmatsevtika sanoati Arxivlandi 2008 yil 16-may kuni Orqaga qaytish mashinasi PricewaterhouseCoopers
• Xitoyda farmatsevtika sanoati - intellektual mulkni himoya qilish, narxlar va innovatsiyalar Arxivlandi 2008 yil 22 iyun Orqaga qaytish mashinasi Rivojlanayotgan iqtisodiyot instituti, Yaponiya tashqi savdo tashkiloti
• Xitoyning me'yoriy-huquqiy bazasiga umumiy nuqtai, China Drug Consulting

Farmatsevtika siyosati va tarqatilishi

• Xitoy farmatsevtika siyosatini o'rganish - Ziyan Vang, JSST sog'liqni saqlash tizimlari va xizmatlari, dorilar va sog'liqni saqlash texnologiyalari
• Xitoyda giyohvandlik siyosati: qishloq joylarda farmatsevtika tarqatish
• Xitoyda farmatsevtika tarqatish Eliza Yibin Chjou, 2007 yil 1 fevral